These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 35429329)
21. Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM. Sunami K; Matsue K; Suzuki K; Takezako N; Shinagawa A; Sakurai S; Tamakoshi H; Biyukov T; Peluso T; Richardson P Cancer Sci; 2020 Jun; 111(6):2116-2122. PubMed ID: 32297407 [TBL] [Abstract][Full Text] [Related]
22. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646 [TBL] [Abstract][Full Text] [Related]
23. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Perrot A; Delimpasi S; Spanoudakis E; Frølund U; Belotti A; Oriol A; Moreau P; McFadden I; Xia Q; Arora M; Dimopoulos MA Leuk Lymphoma; 2024 Jun; 65(6):833-842. PubMed ID: 38497533 [TBL] [Abstract][Full Text] [Related]
24. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma. Zhou X; Steinhardt MJ; Grathwohl D; Meckel K; Nickel K; Leicht HB; Krummenast F; Einsele H; Rasche L; Kortüm KM Cancer Med; 2020 Aug; 9(16):5819-5826. PubMed ID: 32608149 [TBL] [Abstract][Full Text] [Related]
25. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. Hou J; Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; Wortman-Vayn H; Chen N; Mei J; Wang J J Hematol Oncol; 2013 Jun; 6():41. PubMed ID: 23782711 [TBL] [Abstract][Full Text] [Related]
26. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison. Van Sanden S; Ito T; Diels J; Vogel M; Belch A; Oriol A Oncologist; 2018 Mar; 23(3):279-287. PubMed ID: 29192016 [TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S; Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Dimopoulos MA; Hungria VTM; Radinoff A; Delimpasi S; Mikala G; Masszi T; Li J; Capra M; Maiolino A; Pappa V; Chraniuk D; Osipov I; Leleu X; Low M; Matsumoto M; Sule N; Li M; McKeown A; He W; Bright S; Currie B; Perera S; Boyle J; Roy-Ghanta S; Opalinska J; Weisel K Lancet Haematol; 2023 Oct; 10(10):e801-e812. PubMed ID: 37793771 [TBL] [Abstract][Full Text] [Related]
32. Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma. Matsue K; Iwasaki H; Chou T; Tobinai K; Sunami K; Ogawa Y; Kurihara M; Midorikawa S; Zaki M; Doerr T; Iida S Cancer Sci; 2015 Nov; 106(11):1561-7. PubMed ID: 26292221 [TBL] [Abstract][Full Text] [Related]
33. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618 [TBL] [Abstract][Full Text] [Related]
34. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484 [TBL] [Abstract][Full Text] [Related]
35. Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK Future Oncol; 2018 Dec; 14(30):3111-3121. PubMed ID: 30136602 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma. Dima D; Mansour R; Davis JA; Minchak M; Goel U; Atallah R; Logan E; Tabak C; Rashid A; Ahmed N; Abdallah AO; Hashmi H Eur J Haematol; 2024 Jun; 112(6):975-983. PubMed ID: 38382632 [TBL] [Abstract][Full Text] [Related]
37. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study. Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372 [TBL] [Abstract][Full Text] [Related]
38. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series. Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321 [No Abstract] [Full Text] [Related]
39. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Mateos MV; Spencer A; Nooka AK; Pour L; Weisel K; Cavo M; Laubach JP; Cook G; Iida S; Benboubker L; Usmani SZ; Yoon SS; Bahlis NJ; Chiu C; Ukropec J; Schecter JM; Qin X; O'Rourke L; Dimopoulos MA Haematologica; 2020; 105(2):468-477. PubMed ID: 31221782 [TBL] [Abstract][Full Text] [Related]
40. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma. Piggin A; Prince HM Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]